Therapeutic innovation in pancreatic cancer
of our research axis
Pancreatic cancer, or pancreatic adenocarcinoma (PDAC), will soon become the second leading cause of cancer deaths worldwide, due to late diagnosis and lack of effective treatment. Our research effort is dedicated to the development of new strategies to improve the management of patients with this cancer.
In this context, our research objective is to better understand the mechanisms of PDAC oncogenesis and therapeutic resistance. In particular, we are studying the role of genome remodelling and replication in gene expression and resistance to DNA-breaking agents (Project 1). We are deciphering the proteins and protein-protein interactions involved in pancreatic oncogenesis and resistance to treatment using intracellular antibodies (Project 2). Finally, we are investigating the mechanisms responsible for the resistance of cancer cells to oncolytic viruses, and studying the impact of these viruses on the anti-tumour immune response (Project 3).
The overall goal of this research project is to translate our basic research findings into tangible therapeutic innovations for pancreatic cancer patients, using a precision medicine approach.
Regulation of gene expression
Mechanisms of infection by oncolytic viruses and new approaches to immunotherapy
Louis Buscail, Pierre Cordelier
Oncoproteins and protein-protein interactions involved in therapeutic resistance
Role of genome remodelling and replication in gene expression and therapeutic resistance
partnerships & Funding
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?